Busulfan in Pregnancy

Publisher Website
Google Scholar
Abstract
THE MANAGEMENT of chronic granulocytic leukemia during pregnancy causes much concern among clinicians, because the agents effective in the therapy of this malignant disorder are highly toxic and potentially injurious to fetal development. It has been axiomatic that any treatment given to the mother during pregnancy should not endanger the fetus, and therapy be administered only when the patient is symptomatic.1 Some have suggested that all chemotherapy be avoided during the first trimester of pregnancy because of the danger of abortion or deformity.2 This is not always possible, because the patient may conceive while on chemotherapy, or the physician may begin treatment before becoming aware that the patient is pregnant. The number of patients with chronic granulocytic leukemia treated with chemotherapeutic agents during this critical period is few. Reporting the results of such therapy during the period of organogenesis and differentiation is of great importance. The case described